I
InGeneron
Enable novel, safe, and evidence-based therapies that unlock the healing potential of each patient's own regenerative cells
About InGeneron
InGeneron operates in the regenerative medicine sector, focusing on developing and commercializing therapies that utilize patients' own regenerative cells to promote healing. The company targets healthcare providers and patients seeking advanced treatment options for various medical conditions. InGeneron's business model revolves around the research, development, and eventual commercialization of its proprietary RT System, which is currently for investigational use in the US. Revenue generation is anticipated through the sale of these systems and associated therapies once regulatory approvals are secured. The company leverages a team with extensive experience in healthcare, scientific research, and financial management to drive its mission forward. Key personnel include Fabian Alt, with a background in investment banking and capital markets, and Glenn Winnier, who brings over 15 years of scientific leadership and commercialization experience. InGeneron's market strategy is to translate robust scientific research into proven patient benefits, positioning itself as a leader in the regenerative medicine field.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2006
- Headquarters
- Houston, United States
- Employees
- 15
- Open positions
- None listed
- Dealroom signal
- 35.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Alternative Medicine, Biotechnology, Stem Cells, Biotech and Pharma, Hard Tech, DT and LS, start2 group, German Accelerator, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES D✓Equity / VC | Jun 2019 | $23M | $92M | Sanford Health | — |
| EARLY VC✓Equity / VC | Mar 2017 | $20M | $80M | Sanford Health | — |
Growth signals
Latest recorded traffic for InGeneron is 2K monthly website visits, up 11.1% over the last three months. InGeneron's team declined 16.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Sanford Health
Other known investors1 additional known investor
German Accelerator
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about InGeneron on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See InGeneron’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.